Back to News
Market Impact: 0.2
GSK Reveals Positive Early Data For Ris-Rez In Extensive-stage Small Cell Lung Cancer
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
GSK announced the first global data for risvutatug rezetecan (Ris-Rez), its investigational B7-H3-targeted antibody-drug conjugate, in patients with relapsed extensive-stage small cell lung cancer. The article provides no data results, trial outcomes, or numerical figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
GSK0.40
More News
- SAP's Signavio hit with function injunction in Germany
- Jefferies backs GSK with 2,500p target after positive lung cancer drug results
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Nscale, Anthropic Eye $45 Billion Cloud Deal as AI Trade Rebounds
- Elice shares plunge 28% on debut as investor doubts over AI trade deepen
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind's Data Standardization Methodology: Our Approach to Fundamentals
- What Makes Financial Data Ready for AI Research?